Effect of Azithromycin on Failure Proportion of Severe Periodontitis Non-surgical Treatment (AZITHROPARO)

  • End date
    Nov 2, 2024
  • participants needed
  • sponsor
    University Hospital, Strasbourg, France
Updated on 26 August 2023


Primary purpose: Evaluate the effect of azithromycin on failure proportion of severe chronic periodontitis non-surgical treatment; failure characterized by the persistence of at least one periodontal pocket> 5mm at 6 months

Secondary purpose:

  • Evaluate the effect of azithromycin on the persistence of pathological periodontal pockets > 5mm during non-surgical treatment of severe chronic periodontitis at 3 months and 6 months
  • Evaluate the effect of azithromycin on the changes of clinical signs, periopathogen levels, expression of macrolides resistance genes, and expression of antimicrobial peptides (PAMs) during treatment of severe chronic periodontitis at 3 months and 6 months
  • Assess therapeutic observance and side effects of antibiotic treatment
  • Assess at 3 and 6 months the potential interactions of local, bacterial (periopathogen and resistance gene) clinical factors, and host defense (PAMs) with the effect of azithromycin, on failure proportion of severe chronic periodontitis non-surgical treatment

Condition Severe Chronic Periodontitis
Treatment Non-surgical periodontal treatment and azithromycin treatment, Non-surgical periodontal treatment and placebo treatment
Clinical Study IdentifierNCT04198649
SponsorUniversity Hospital, Strasbourg, France
Last Modified on26 August 2023


Yes No Not Sure

Inclusion Criteria

Patient with severe generalized chronic periodontitis (loss of attachment ≥ 5mm at > 30% sites) (AAP classification 1999) and periodontal pockets >5mm on at least 5% of sites
presence of bleeding on probing (≥ 30%)
male or female subject older than 35 Years
patient with at least 15 teeth including at least 2 molars (excluding wisdom teeth)
patient with social assurance
voluntary patient who signed informed consent

Exclusion Criteria

Patient with contraindications to treatment with azithromycin or its excipient: absolute contraindications are the history of allergy to macrolides or one of the excipients used in this study, association with ergot derivatives Rye, Cisapride, colchicine, and severe hepatic deficiencies. Other contraindications are for patients at risk of cardiac arrhythmia (diagnosis of QT interval prolongation and/or concomitant treatments, electrolytic disorder (hypokalemia, hypomagnesemia, cardiac arrhythmia, heart failure), severe renal failure, and drug associations (Antivitamin K, statins)
Patient with aggressive periodontitis (AAP classification 1999)
Patient smoking more than 10 cigarettes/day
Patient with endocarditis risk or requiring antibiotic prophylaxis
Patient with antibiotic treatment within 6 months prior to periodontal examination
Patient with anti-inflammatory treatment in the month preceding periodontal examination and/or anti-inflammatory treatment of more than 3 consecutive days in the 3 months preceding periodontal examination
Patient following or having followed a drug treatment (cyclosporine and other anti-rejection drugs, antiepileptic, calcium inhibitor) influencing periodontal status
Patient with pathologies influencing periodontal status and/or systemic or local inflammatory response, such as diabetes, infectious stomatitis or not, diseases inflammatory and autoimmune, immuno-depression
Patient with prolonged oral hygiene disability (physical/psychic impossibility of brushing teeth)
Patient with impaired oral condition (untreated cavities, non-dental teeth rehabilitated), dental infections whose management requires antibiotic treatment within 6 months
Patient having specialized periodontal treatment, root planning, or a periodontal surgical treatment in the year prior to the examination
Pregnant woman or breastfeeding
Patient with repeated chronic infections (more than 3 times per year) requiring antibiotic treatment
Patient who had oral antiseptic treatment in the previous month
Patient included in another intervention research protocol or in periods of exclusion (participation in an observational study remains possible)
Patient with high bleeding risk and/or INR > 4\
Patient under guardianship and under protection of justice
Patient unable to cooperate or understand the instructions related to the study and care
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note